Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Hansoh Pharmaceutical Group Company Limited
翰森製藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3692)

VOLUNTARY ANNOUNCEMENT

MARKETING AUTHORIZATION OF AUMOLERTINIB RECEIVES POSITIVE OPINION FROM THE CHMP OF THE EMA

Reference is made to the announcements of Hansoh Pharmaceutical Group Company Limited (the "**Company**", together with its subsidiaries, the "**Group**") dated September 27, 2026 and October 11, 2026 in respect of the update on the marketing authorization status of Aumolertinib, marketed as Aumseqa® outside China, in the European Union (EU). Unless the context otherwise requires, capitalized words and expressions used herein shall have the same meanings as defined in the said announcements.

The board of directors (the "**Board**") of the Company announces that, on November 12, 2026, the Committee for Medicinal Products for Human Use ("**CHMP**") of the European Medicines Agency ("**EMA**") adopted a positive opinion, recommending the granting of a marketing authorization (the "**MA**") for Aumolertinib, intended for the treatment of non-small cell lung cancer (NSCLC).

The MA is subject to final approval by the European Commission (EC). The shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By Order of the Board
Hansoh Pharmaceutical Group Company Limited
Zhong Huijuan
Chairlady

Hong Kong, November 15, 2026

As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Ms. Sun Yuan and Dr. Lyu Aifeng as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai, Ms. Yang Dongtao and Mr. Yan Jia as independent non-executive directors.